Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Spiriva].

J L Corhay1, R Louis

  • 1Service de Pneumologie, CHU Sart-Tilman, B 35 4000 Liège, Belgique.

Revue Medicale De Liege
|November 24, 2004
PubMed
Summary
This summary is machine-generated.

Tiotropium, a once-daily bronchodilator, effectively treats chronic obstructive pulmonary disease (COPD). It improves lung function, quality of life, and reduces exacerbations in moderate to very severe COPD patients.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Synbiotic Bactecal® reduces airway obstruction, sputum eosinophils and IL-4 but increases sputum IL-8 in patients with uncontrolled asthma" [Cytokine 202 (2026) 157145].

Cytokine·2026
Same author

Synbiotic Bactecal® reduces airway obstruction, sputum eosinophils and IL-4 but increases sputum IL-8 in patients with uncontrolled asthma.

Cytokine·2026
Same author

Author Correction: Forced oscillation technique in progressive pulmonary fibrosis in a single-center retrospective study.

Scientific reports·2026
Same author

Forced oscillation technique in progressive pulmonary fibrosis in a single-center retrospective study.

Scientific reports·2025
Same author

Allergic Rhinitis and its Impact on Asthma (ARIA) Classes in MASK-air Users.

Journal of investigational allergology & clinical immunology·2025
Same author

Increase in Blood Eosinophil Count Over Time and Sputum IL8 are Associated with FEV<sub>1</sub> Decline in Asthma.

Lung·2024
Same journal

[Nature prescriptions and health promotion : sharing experience from primary care].

Revue medicale de Liege·2026
Same journal

[Eco-health: shared perspectives on primary care practice].

Revue medicale de Liege·2026
Same journal

[The strategic role of primary care in emerging diseases : surveillance, research, and preparedness].

Revue medicale de Liege·2026
Same journal

[Environmental impact of medicines and approaches for more eco responsible use].

Revue medicale de Liege·2026
Same journal

[Climate change and skin].

Revue medicale de Liege·2026
Same journal

[From Silent Spring to neuronal silence : pesticides and neurodegenerative diseases].

Revue medicale de Liege·2026
See all related articles

Area of Science:

  • Pharmacology
  • Respiratory Medicine

Context:

  • Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease.
  • Management of COPD requires effective long-term bronchodilation.

Purpose:

  • To evaluate the efficacy and tolerability of tiotropium for COPD treatment.
  • To assess the impact of tiotropium on spirometry, quality of life, and exacerbations.

Summary:

  • Tiotropium is a long-acting anticholinergic bronchodilator administered once daily.
  • It acts by antagonizing acetylcholine at M3-muscarinic receptors, relaxing airway smooth muscle.
  • Clinical studies demonstrate its efficacy and good tolerance in moderate to very severe COPD.

Impact:

  • Tiotropium improves spirometric measurements in COPD patients.
  • It enhances quality of life and reduces symptoms like dyspnea.
  • Once-daily tiotropium significantly reduces the rate of COPD exacerbations.